Jenoptik aims for flotation in 1998:
This article was originally published in Clinica
Executive Summary
Jenoptik's chairman Lothar Spath intends to float the German company, currently 100%-owned by the Thuringian government, on the stock exchange in 1998, says a report in Handelsblatt. The company recently announced the concentration of its medical technology business in a new joint venture with Aesculap (see Clinica No 661, p 1) and has restructured its remaining businesses into three separate operating companies focusing on microproduction and sterile space technology; automation technology and quality mechanics; and laser and optical technology. Jenoptik's sterile space subsidiary Meissner+Wurst, which expects to achieve turnover of DM 500 million and a profit of DM 10 million this year, has formed a biotechnology joint venture with Life Sciences International, Stuttgart.